Skip to main content

Nonprofit · EIN 91-1766321

THE AMERICAN SOCIETY OF GENE & CELL THERAPY

Tax-exempt · WAUKESHA, WI 53186

Financials

$16.4M$13.8M2023$16.9M$14.6M2024
Revenue Expenses · by fiscal year end
Financials of THE AMERICAN SOCIETY OF GENE & CELL THERAPY by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2024990$16,914,337$14,579,126$2,335,211$27,046,811$6,736,956$20,309,855
December 31, 2023990$16,370,708$13,754,627$2,616,081$23,810,378$6,597,384$17,212,994
Financial details: 990 for the year ended December 31, 2024

Revenue

Contributions, gifts and grants
$229,856
Program service revenue
$15,624,301
Investment income
$1,024,374
Other revenue
$35,806

Expenses

Grants and similar amounts paid
$1,266,770
Compensation of officers, directors and key employees
$618,447
Other salaries and wages
$3,794,784
Salaries, compensation and benefits (total)
$5,250,736
Professional fundraising fees
$0
Legal fees
$8,808
Accounting fees
$86,164
Occupancy
$235,003
Travel
$558,905
Depreciation
$55,094
Program services (functional)
$11,680,451
Management and general (functional)
$2,075,815
Fundraising (functional)
$822,860

Balance sheet and other

Total assets, start of year
$23,810,378
Total assets, end of year
$27,046,811
Total liabilities, end of year
$6,736,956
Net assets, end of year
$20,309,855
Land, buildings and equipment
$85,447
Publicly traded securities
$23,855,045
Net assets without donor restrictions
$19,672,466
Net assets with donor restrictions
$637,389
Gross unrelated business income
$28,411
Gross receipts
$16,914,337
Employees
48
Volunteers
19
Year formed
1996
State of legal domicile
WA

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2024, highest compensation first.

NameTitleHours / weekCompensationOther / benefits
DAVID BARRETTEXECUTIVE DIRECTOR
Officer
40$577,778$40,669
MARGARITA LEA VALDEZEMPLOYEE
Highest-paid employee
40$242,394$7,272
LAURA MICHELLE GALLAGHEREMPLOYEE
Highest-paid employee
40$215,407$15,816
RYAN HIETPASEMPLOYEE
Highest-paid employee
40$169,899$14,949
KELLIE BEUMEREMPLOYEE
Highest-paid employee
40$153,501$19,493
JEAN NORTONEMPLOYEE
Highest-paid employee
40$139,261$24,148
JEFFREY S CHAMBERLAIN PHDPAST PRESIDENT
Trustee or director, Officer
5$0$0
HANS-PETER KIEM MD PHDPAST PRESIDENT
Trustee or director, Officer
5$0$0
PAULA CANNON PHDPRESIDENT
Trustee or director, Officer
5$0$0
MATTHEW PORTEUS MD PHDVICE PRESIDENT
Trustee or director, Officer
5$0$0
CLAIRE BOOTH MBBS PHDPART YEAR DIRECTOR
Trustee or director
3$0$0
KIMBERLY GOODSPEED MDPART YEAR DIRECTOR
Trustee or director
3$0$0
FEDERICO MINGOZZI PHDTREASURER
Trustee or director, Officer
5$0$0
HILDEGARD BUNING PHDPART YEAR DIRECTOR
Trustee or director
3$0$0
MIGUEL SENA-ESTEVES PHDPART YEAR DIRECTOR
Trustee or director
3$0$0
10 more people on this return
NameTitleHours / weekCompensation
MARIA-GRAZIA RONCAROLO MDPART YEAR DIRECTOR
Trustee or director
3$0
RAYNE H ROUCE MDPART YEAR DIRECTOR
Trustee or director
3$0
TERENCE R FLOTTE MDPRESIDENT ELECT
Trustee or director, Officer
5$0
ISABELLE RIVIRE PHDSECRETARY
Trustee or director, Officer
5$0
ARAVIND ASOKAN PHDDIRECTOR
Trustee or director
3$0
DANIEL E BAUER MD PHDDIRECTOR
Trustee or director
3$0
LINDSEY GEORGE MDDIRECTOR
Trustee or director
3$0
PUNAM MALIK MDDIRECTOR
Trustee or director
3$0
KAH-WHYE PENG PHDDIRECTOR
Trustee or director
3$0
JENNIFER WELLMAN MSDIRECTOR
Trustee or director
3$0
990 for the year ended December 31, 2023: 25 people
NameTitleHours / weekCompensationOther / benefits
DAVID BARRETTEXECUTIVE DIRECTOR
Officer
40$432,985$36,376
LAURA MICHELLE GALLAGHEREMPLOYEE
Highest-paid employee
40$193,488$14,798
MARGARITA LEA VALDEZEMPLOYEE
Highest-paid employee
40$196,383$5,891
GRANT HOLLEYEMPLOYEE
Highest-paid employee
40$136,659$10,654
BETTY SCHIEFELBEINEMPLOYEE
Highest-paid employee
40$126,173$3,795
ALEX WENDLANDEMPLOYEE
Highest-paid employee
40$126,061$3,782
BEVERLY DAVIDSON PHDPAST PRESIDENT
Trustee or director, Officer
5$0$0
HANS-PETER KIEM MD PHDPAST PRESIDENT
Trustee or director, Officer
5$0$0
JEFFREY S CHAMBERLAIN PHDPRESIDENT
Trustee or director, Officer
5$0$0
TERENCE R FLOTTE MDVICE PRESIDENT
Trustee or director, Officer
5$0$0
PALOMA H GIANGRANDE PHDPART YEAR TREASURER
Trustee or director, Officer
5$0$0
ANASTASIA KHVOROVA PHDPART YEAR DIRECTOR
Trustee or director
3$0$0
FEDERICO MINGOZZI PHDPART YEAR TREASURER
Trustee or director, Officer
5$0$0
HILDEGARD BUNING PHDDIRECTOR
Trustee or director
3$0$0
MARCELA V MAUS MD PHDPART YEAR DIRECTOR
Trustee or director
3$0$0
MARIA-GRAZIA RONCAROLO MDDIRECTOR
Trustee or director
3$0$0
RAYNE H ROUCE MDDIRECTOR
Trustee or director
3$0$0
PAULA CANNON PHDPRESIDENT ELECT
Trustee or director, Officer
5$0$0
ISABELLE RIVIRE PHDSECRETARY
Trustee or director, Officer
5$0$0
ARAVIND ASOKAN PHDDIRECTOR
Trustee or director
3$0$0
DANIEL E BAUER MD PHDDIRECTOR
Trustee or director
3$0$0
LINDSEY GEORGE MDDIRECTOR
Trustee or director
3$0$0
PUNAM MALIK MDDIRECTOR
Trustee or director
3$0$0
KAH-WHYE PENG PHDDIRECTOR
Trustee or director
3$0$0
JENNIFER WELLMAN MSDIRECTOR
Trustee or director
3$0$0

Address and contacts

Address (IRS master file)
20700 SWENSON DR STE 200, WAUKESHA, WI 53186-0904
In care of
% DR GEORGE STAMATOYANNOPOULOS PRES
Principal officer (990 for 2024)
FEDERICO MINGOZZI PHD, 20800 SWENSON DR 300, WAUKESHA, WI 53186
Signed the 990
FEDERICO MINGOZZI PHD, TREASURER
Phone
(414) 278-1341
Return prepared by
RITZ HOLMAN LLP

Mission

ASGCT'S MISSION IS TO ADVANCE KNOWLEDGE, AWARENESS, AND EDUCATION LEADING TO THE DISCOVERY AND CLINICAL APPLICATION OF GENETIC AND CELLULAR THERAPIES TO ALLEVIATE HUMAN DISEASE.

990 for the year ended December 31, 2024

Program accomplishments

  • ANNUAL MEETING: THIS IS THE PRIMARY VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE ANNUAL MEETING REPRESENTS THE MAJOR EDUCATIONAL INITIATIVE OF THE SOCIETY.
    Expenses $6,234,014 · grants $44,000 · revenue $10,697,682
  • MOLECULAR THERAPY JOURNALS: PUBLISHING SCHOLARLY JOURNALS IS THE SECOND MAJOR VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE JOURNALS ARE THE WAY ASGCT EDUCATES AND UPDATES RESEARCHERS, CLINICIANS, AND STUDENTS ON THE LATEST ADVANCES IN THE DEVELOPMENT OF NOVEL THERAPEUTICS.
    Expenses $1,042,691 · grants $191,655 · revenue $3,056,873
  • ADVOCACY: ADVOCACY IS THE THIRD MAJOR VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE DEFINING VALUE OF ADVOCACY IS "GENE AND CELL THERAPY WILL HAVE A FINANCIAL IMPACT ON PATIENTS, PROVIDERS, AND PAYERS. ASGCT IS COMMITTED TO UNDERSTANDING THAT IMPACT AND EDUCATING DECISION-MAKERS ENGAGED IN DEVELOPING POLICIES THAT INFLUENCE PATIENT ACCESS TO TREATMENTS."
    Expenses $850,215 · grants $25,000
  • OTHER PROGRAMS INCLUDE: WORKSHOPS, INTERNATIONAL ONCOLYTIC VIRUS CONFERENCE, POLICY SUMMIT, CAREER DEVELOPMENT PROGRAM, DIVERSITY AND INCLUSION COMMITTEE, CAREER DEVELOPMENT PROGRAM PATIENT EDUCATION PROGRAM, AND THE NEWSLETTER.
    Expenses $3,553,531 · grants $1,006,115 · revenue $1,877,141

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026Not on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990 on file

IRS record

EIN
91-1766321
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
1997
Accounting year ends
December
Files
Form 990 or 990-EZ
Category (NTEE)
Medical research (H20)
Assets (IRS master file)
$27,046,811
Income (IRS master file)
$16,914,337

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2024$16,914,337$14,579,126$27,046,811XML
990-TDecember 2024–––IRS
990December 2023$16,370,708$13,754,627$23,810,378XML
990-TDecember 2023–––IRS
990December 2022$12,483,052$10,958,628$20,486,557IRS
990-TDecember 2022–––IRS
990December 2021–––IRS
990-TDecember 2021–––IRS
990December 2020–––IRS
990-TDecember 2020–––IRS
990December 2018–––IRS
990December 2017–––IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 91-1766321).

Questions about THE AMERICAN SOCIETY OF GENE & CELL THERAPY

What is the EIN of THE AMERICAN SOCIETY OF GENE & CELL THERAPY?
The employer identification number (EIN) of THE AMERICAN SOCIETY OF GENE & CELL THERAPY is 91-1766321.
Is THE AMERICAN SOCIETY OF GENE & CELL THERAPY tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1997.
Are donations to THE AMERICAN SOCIETY OF GENE & CELL THERAPY tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does THE AMERICAN SOCIETY OF GENE & CELL THERAPY file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of THE AMERICAN SOCIETY OF GENE & CELL THERAPY due?
The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
When did THE AMERICAN SOCIETY OF GENE & CELL THERAPY last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2024.
Who is the principal officer of THE AMERICAN SOCIETY OF GENE & CELL THERAPY?
The 990 for the year ended December 31, 2024 names FEDERICO MINGOZZI PHD.
Who are the officers and directors of THE AMERICAN SOCIETY OF GENE & CELL THERAPY?
The 990 for the year ended December 31, 2024 lists 25 people; 6 received compensation from the organization, the highest $577,778 (DAVID BARRETT, EXECUTIVE DIRECTOR).
How much revenue does THE AMERICAN SOCIETY OF GENE & CELL THERAPY have?
On its 990 for the year ended December 31, 2024 it reported revenue of $16,914,337, expenses of $14,579,126 and total assets of $27,046,811 at year end.

Other nonprofits in WAUKESHA

All nonprofits in WAUKESHA · Wisconsin · Medical research